|
J&J Gives Thumbs Down to Biosimilars, Sees No Opportunity
Cash-rich Johnson & Johnson (J&J) is ready to strike on opportunities this year to purchase pharmaceutical or life science assets at distressed prices, but the company is not interested in biosimilars. Such products will require clinical trials, which mean significant investments, CEO William Weldon said. The company’s position differs from that of rival Merck, which announced its intention last December to enter the biosimilar space.
Drug Industry Daily |
Register Now
Archives